British Health Authorities recently announced their goal of effectively ending HIV in England by 2030, a step closer thanks to GSK’s active collaboration with ViiV Healthcare’s HIV-focused Health Action Alliance. The announcement was made at the White House on World AIDS Day, sponsored by the Department of Health and Human Services US Business Action to End HIV.
The National HIV/AIDS Strategy aims to achieve a target of 90% active eradication by 2030 and engage the private sector to increase access to all sectors of society. Explaining the benefits of involving private organizations and sectors, Lynn Baxter, head of ViiV North America, said in an interview that private organizations could power the project approach because they constantly interact in different places.
The best and most exciting part is that all these public agencies, public health, federal agencies, and pharma companies share the same mission and human values for society as we do. Public health organizations stand ready to collaborate with ViiV to raise awareness of the stigma, discrimination, and structural and interconnected social factors of HIV to meet our goals of ending HIV by 2030.
So, now is the time to be more innovative and inclusive in our observations and approaches to help affected communities understand and connect to care. Otherwise, he believes never to be able to change the situation.
The plan is to expand the project scope to include these day-to-day organizations. They will not be made to follow a specific marketing plan but will use general forms of communication with their audience. Are Twitter, Instagram, Facebook, LinkedIn, etc.
Some of the big names that have agreed and are cooperating with British health authorities are Ada Health, Avita Pharmacy, BLK, Chispa, CVS, Healthvana, National LGBT Chamber of Commerce, OraSure Technologies, The Powell Companies Real, Tinder, Uber, Walgreens, and Walmart.
Further no-drop measures were also discussed and subsequently evolved, which are as follows: making HIV a corporate priority and proactively informing other industry leaders; educating members of the workplace about combating HIV stigma in the workplace; strengthening both HIV coverage and non-discrimination policies for employees; Advocating for better HIV policies and related systemic reforms; Implementation of innovative strategies in communities most affected by HIV; and finally providing funding to strengthen the Federation’s public health response.
ViiV is a fully HIV-focused therapeutics pharma company that is a leader with a strong drive on diverse social and societal issues. Its portfolio includes Dovato, which was greenlit, in 2019 and generated 787 million pounds ($940 million) in 2021, as recorded under GSK. The company is expected to make £7 billion by 2026. Also, ODDO BHF analysts estimated in a note to clients in October that the cabotegravir franchise — which currently includes Cabinova treatment and Apretude for PrEP — could reach near-peak sales of £3. billion in 2030.